Audit: QRS - LSD for Health & Longevity

Audit conducted on 01/10/2026 09:12 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	84
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Lede, protocol, time-to-effect, gates, tiers, markers and cadence all traced to ER passages (Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions, Monitoring)
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges kept: “controlled trials have not shown benefit over placebo”, “reportedly”, “reported to”, “evidence conflicted”, “aging effects unknown”
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Definium Therapeutics, Liechti group/Basel, Peter Gasser, James Fadiman appear only in ER Protocol labels; no PMIDs or NCT IDs
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and Marker/Target/Why headers match the template
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template data-qrs-var spans present (marker_#/qualitative_item_# expanded to 8 and 7 rows)
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Template diff shows only data-qrs-var content and metadata changed; website spans untouched

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	N/A — no source ER section used by the QRS is empty; no empty-state phrasing needed
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji found in QRS source; ER “⚠️ Conflicted” rendered as text
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	duration “00:02” quoted because it contains a colon; other values unquoted and trimmed
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.9.29 matches QRS.md version
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-1001-0842 → 10/01/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words (script count)
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All nine ER “Populations who should avoid LSD” bullets represented
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Thresholds and windows kept: ≥140/90 mmHg, <6 months, moderate or worse, past 12 months, Child-Pugh Class C
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	N/A — ER contraindication bullets use no ranking notation
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	N/A — section is populated

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eleven ER interactions listed; lithium (contraindication) correctly excluded
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	N/A — ER interaction bullets use no ranking notation
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	N/A — section is populated

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Single-dose clinical protocol, LSD-assisted psychotherapy, microdosing — the three ER regimens
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	N/A — ER Protocol names three distinct regimens; all three sets used
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Anxiety/mood onset and persistence (High tier) precede longer sleep (Medium tier)
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	N/A — ER provides at least three time-to-effect aspects; all three sets used
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	N/A — ER provides time-to-effect information

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	N/A — all four benefit tiers have items in the ER

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	N/A — all four risk tiers have items in the ER

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 8 ER table biomarkers listed with verbatim targets
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 7 ER qualitative markers listed verbatim

Issues 01/10/2026 09:12

Pass rate 100.00%. No issues found.

Issues 01/10/2026 09:10

1. 14.2 — Pregnancy test omitted from Monitoring: The ER Monitoring baseline (ER line 421) includes “a pregnancy test where relevant”, but the QRS Monitoring section lists it neither in the biomarker table nor in [monitoring_cadence] (QRS line 699).

Fixes 01/10/2026 09:10

1. 14.2 — Pregnancy test added to cadence: Changed [monitoring_cadence] from “Baseline before a first full dose or microdosing course;” to “Baseline before a first full dose or microdosing course, including a pregnancy test where relevant;”, matching the ER Monitoring baseline.

Issues 01/10/2026 09:06

1. 2.5 — Interaction lines read as directives: Key Interactions lines 567-568 state “abstinence for 24 hours around dosing” and “no driving or hazardous work for 24 hours” as instructions, whereas the ER (lines 332-333) presents them as trial practice (“standard in trials”, “trials exclude them”).
2. 7.5 — Unexplained term “microdoses”: The At a Glance text (line 433) uses “microdoses” without a plain-language explanation; the ER describes them as “tiny” doses (line 39).

Fixes 01/10/2026 09:06

1. 2.5 — Interaction lines reframed as trial practice: Changed “abstinence for 24 hours around dosing” to “24-hour abstinence around dosing is standard in trials” and “no driving or hazardous work for 24 hours” to “trials exclude driving and hazardous work for 24 hours”, matching ER lines 332-333.
2. 7.5 — Explained “microdoses” in lede: Changed repeated "microdoses" to repeated tiny "microdoses" (and hyphenated “blood-pressure rises” to keep the lede at 70 words).

Issues 01/10/2026 09:02

1. 9.5 — Dextromethorphan qualifier dropped: Line 564 lists “dextromethorphan” without the ER’s parenthetical “(a cough suppressant)”, dropping the product-type qualifier that determines whether the interaction applies to a reader.

Fixes 01/10/2026 09:02

1. 9.5 — Dextromethorphan qualifier restored: Changed the interaction label from “… and dextromethorphan:” to “… and dextromethorphan (a cough suppressant):”, restoring the ER’s parenthetical qualifier.

Issues 01/10/2026 08:58

1. 1.2 / 1.3 — Hedged interaction findings stated as fact: Key Interactions drop the ER’s hedging: tricyclics “reported to intensify” became “intensified responses” (line 560), MAO inhibitors “reported to weaken” became “weakened effects” (line 561), and SSRI blunting “described” in a 1996 interview study became “blunted effects” (line 558).
2. 1.2 / 1.3 — Microdosing verdict strengthened in lede: At a Glance (line 433) says “Microdosing showed no lasting benefit beyond expectation”, turning the ER Conclusion’s “has not shown lasting benefits beyond expectation” (absence of evidence) into a definitive negative finding.

Fixes 01/10/2026 08:58

1. 1.2 / 1.3 — Hedged interaction findings restored: Restored the ER’s hedging in Key Interactions: “blunted effects” → “reportedly blunted effects” (SSRIs/SNRIs), “intensified responses” → “reported to intensify responses” (tricyclics), “weakened effects” → “reported to weaken effects” (MAO inhibitors).
2. 1.2 / 1.3 — Microdosing lede verdict softened: Changed At a Glance “Microdosing showed no lasting benefit” to “Microdosing has not shown lasting benefit”, matching the ER Conclusion; dropped “long-acting” to keep the lede at 70 words.

Issues 01/10/2026 08:54

1. 1.1 — SSRI exposure claim overgeneralized: The SSRIs and SNRIs interaction (line 558) says “raised LSD exposure” for the whole class, but the ER (line 323) reports raised exposure only with daily paroxetine.
2. 1.1 — Dextromethorphan effect misstated: The decongestants/dextromethorphan interaction (line 564) says “additive stimulation” for both, but the ER (line 329) attributes serotonin-raising and dissociative effects, not stimulation, to dextromethorphan.
3. 1.1 / 7.4 — Unsupported “mostly company-funded”: At a Glance (line 433) says full-dose trials were “mostly company-funded”; the ER Conclusion says only the large recent trials and the older-adult trial were company-paid.
4. 1.3 — Microdosing verdict strengthened: At a Glance (line 433) drops the ER Conclusion’s exception “apart from a modest lengthening of sleep”, and it narrows the ER’s “psychosis or bipolar illness” to “psychosis” only.

Fixes 01/10/2026 08:54

1. 1.1 — SSRI exposure claim overgeneralized: Changed the SSRIs and SNRIs interaction from “Caution; blunted effects, raised LSD exposure” to “Caution; blunted effects; paroxetine raised LSD exposure”.
2. 1.1 — Dextromethorphan effect misstated: Changed the decongestants/dextromethorphan interaction from “Caution; additive stimulation” to “Caution; additive blood-pressure stimulation; serotonin-raising and dissociative effects”.
3. 1.1 / 7.4 — Unsupported “mostly company-funded”: Replaced “Full-dose trials, mostly company-funded” with “Full-dose trials, the largest company-funded” in At a Glance.
4. 1.3 — Microdosing verdict strengthened: Restored the ER’s sleep exception (“except longer sleep”) and added “or bipolar illness” to the psychiatric-risk group in At a Glance. Trimmed other wording to keep it at 70 words.

Issues 01/10/2026 08:49

1. 7.2 — Legal-access limit omitted: The At A Glance text (QRS line 433) leaves out the ER Conclusion’s point that LSD’s legal status still limits access (ER line 468; Schedule I, legal access limited to trials, ER lines 391 and 405), so the execution-oriented summary does not say the drug is a controlled substance.

Fixes 01/10/2026 08:49

1. 7.2 — Legal-access limit added: Rewrote the At A Glance text to add the ER Conclusion’s “Legal status limits access.” and tightened earlier wording to stay at 69 words (≤70).

Issues 01/10/2026 08:46

1. 1.3 — Lede overstates trial results: The at-a-glance (line 433) says “Supervised full doses brought rapid relief lasting months”, stating as fact what the ER Conclusion presents as trials that “report rapid relief lasting months”, with the large trials still awaiting independent publication.

Fixes 01/10/2026 08:46

1. 1.3 — Lede overstates trial results: Changed “Supervised full doses brought rapid relief lasting months, mostly in company-funded trials” to “Trials of supervised full doses report rapid relief lasting months, mostly company-funded”, matching the ER’s “report” framing (word count stays at 70).